unit state go sg websit
robust better ep guidanc boost us tax reform
upsid tp
nc chang
lilli perform driven better pharma lower tax rate
ep guidanc increas tax rate
lower due us tax reform vs initi guidanc
challeng greater impact rebat insulin although
market continu expand dynam us
mean mix read-across novo sanofi
decemb us diabet environ
robust driven endocrinolog anim health still soft group sale grew
cc constant currenc consensu estim thank robust
perform endocrinolog drug trulic diabet weekli
direct competitor novo victoza beat consensu stoke
help drug still gain signific market share top threshold
us humalog short-act insulin declin slower expect despit price
pressur forteo osteoporosi beat consensu help
one-off posit price impact basaglar biosimilar version sanofi lantu
consensu expect us sale almost flat vs due higher
rebat situat neg read-across sanofi us sale risk repres
novo us sale risk repres confirm continu price
pressur us insulin market anim health group sale remain
pressur cc despit recoveri observ food busi still
challeng strateg review on-going compani provid updat
result plan adjust ep reach consensu
thank lower tax rate due us tax reform
sale guidanc reiter adjust ep guidanc rais thank lower tax
rate sale non-gaap ep vs
ep initi guidanc tax rate initi guidanc provid
decemb vs adjust estim reflect better
perform lower tax rate updat tp accordingli vs
like peer lilli record one-tim tax charg correspond
net impact repatri tax chang differ tax hold
reiter lilli enjoy biotech-lik profil consensu expect pipelin
alreadi high valuat premium vs sector price-to-earnings alreadi
reflect ep growth slightli sector
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
simplifi main product
lilli result conf call feedback question us diabet price
environ still challeng tax reform
price pressur continu across board long-act insulin basaglar direct
competitor sanofi lantu novo levemir tresiba neg read-across
european compani state initi comment comment potenti entri
new lantu biosimilar view merck co interchang
within biosimilar possibl scenario us accord lilli flag sanofi
wont happen year even best case mani hurdl overcom
unlik impact forese futur
class support strong volum
trulic beat consensu good perform partial explain
stock impact even adjust factor still estim
class benefit volum growth us direct competitor novo
victoza cardiovascular outcom studi call rewind expect year help
trulic compet
new once-weekli product
novo
ozempic/semaglutid launch
trulic us market prescript
basaglar us prescript total/trx new brand/nbrx
oral posit still unclear stage
sever question novo oral semaglutid phase programm read
potenti impact diabet franchis lilli warn poor
bio-avail profil novo drug risk gastro-intestin side effect food interact
rather inconveni need wait minut meal intak lilli
develop version current pre-clin look much better bio-
avail moreov lilli flag challeng valu proposit high price oral
semaglutid vs avail oral product cardiovascular benefit
lilli jardianc comment support cautiou view novo oral semaglutid
project challeng posit stage question safeti conveni
taltz perform line
regard taltz dermatolog direct competitor novarti cosentyx compani
excit new indic rheumatolog compet
novarti interestingli acceler taltz prescript us bit softer vs
market growth suggest novarti cosentyx massiv impact lilli
report last week swiss compani
us share biolog dermatologist prescript
us new brand prescript nbrx breast cancer
tax rate guidanc sustain may even optim futur
greater clariti tax reform mean could decreas
import outcom data readout diabet
import late-stag pipelin news view diabet front
outcom trial result
trulic weekli rewind patient posit would
anoth demonstr benefit class far novo victoza
demonstr cardiovascular benefit although modest prospect studi wherea
tradjenta linagliptin dpp-iv two trial carolina vs sulfonylurea glimepirid
carmelia vs best standard care
newsflow meaning regulatori event other
regulatori front us approv oluminat baricitinib rheumatoid arthriti
import mileston although anticip green light despit question safeti
fda advisori committe like take place final fda decis
accord compani new safeti signal
valuat tp increas vs mainli reflect lower tax rate
part
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet jan cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
tp deriv sotp premium vs pharma anim health dcf lt growth lt ebita margin wacc
downsid failur pipelin project cancer mid-singl digit stronger competit fast follow product cancer immune-
inflamm high singl digit
upsid better penetr talz psoriasi high-single-digit upsid ebit
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ bond
